Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03147287
Title Palbociclib After CDK and Endocrine Therapy (PACE)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications

Her2-receptor negative breast cancer

Therapies

Palbociclib

Fulvestrant + Palbociclib

Avelumab + Fulvestrant + Palbociclib

Fulvestrant

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST